SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection at Alembic Pharmaceuticals’ Panelav units

30 Jun 2016 Evaluate

Alembic Pharmaceuticals' API Facilities i.e. API I and API II both located at Panelav have been successfully inspected by the USFDA between June 20, 2016 and June 29, 2016. The company did not receive any Form 483 observations.

Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification. The launch of this product will be based on the outcome of the ongoing litigation in the United States District Court for the District of Delaware with UCB. Alembic now has a total of 47 ANDA approvals (43 Final approvals and 4 tentative approvals) from USFDA.

Alembic Pharma Share Price

759.00 -25.95 (-3.31%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×